Expand VRCA Menu
VRCA MENU

VRCA Latest Press Releases

-- January 7, 2026 --

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts Globe Newswire 8:00 AM

-- November 24, 2025 --

Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway Globe Newswire 8:00 AM

-- November 14, 2025 --

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results Globe Newswire 4:05 PM

-- November 10, 2025 --

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting Globe Newswire 8:00 AM

-- October 24, 2025 --

Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights Business Wire 11:00 AM

-- October 20, 2025 --

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH in the European Union Globe Newswire 4:05 PM

-- October 7, 2025 --

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting Globe Newswire 4:05 PM

-- September 19, 2025 --

Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH (TO-208) in Japan for the Treatment of Molluscum Contagiosum Globe Newswire 8:00 AM

-- September 2, 2025 --

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference Globe Newswire 7:00 AM

-- August 12, 2025 --

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results Globe Newswire 4:01 PM
Market Data Delayed 15 Minutes